Full Press Release Details
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Under